Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology
The US-based pharmaceutical company has kicked off a big management reshuffle after a top-level decision ordered independent units for neuroscience and immunology, with the latter handling a potential launch of Alzheimer's drug donanemab.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
Oncology and the larger Bio-Medicines division will be hit particularly hard now that Eli Lilly initiates a series of larger organizational changes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
.jpg)
Eli Lilly specifies guidance for this year's revenue
For subscribers
.jpg&w=384&q=75)
